What is the difference between acute tubular necrosis and glomerulonephritis?

Acute Tubular Necrosis vs Glomerulonephritis: Key Distinctions

Acute tubular necrosis (ATN) and glomerulonephritis (GN) are fundamentally different kidney pathologies: ATN is tubular epithelial cell injury typically from ischemia or toxins affecting the tubules, while GN is immune-mediated or complement-driven inflammation primarily targeting the glomeruli.

Anatomic Location and Pathophysiology

ATN affects the renal tubules with characteristic findings including tubular cell necrosis, sloughing, epithelial flattening, and tubular dilatation 1. The injury occurs from direct tubular toxicity (aminoglycosides, cisplatin), renovasoconstriction (NSAIDs), or ischemic insults 2, 3.

GN affects the glomeruli through five distinct pathogenic mechanisms 4, 5:

• Immune complex-mediated GN (lupus nephritis, IgA nephropathy)
• ANCA-associated GN (80-90% have circulating ANCA against MPO or PR3)
• Anti-GBM GN (linear IgG deposits along basement membrane)
• Monoclonal immunoglobulin-mediated GN
• C3 glomerulopathy (dominant C3 deposits with minimal immunoglobulin)

Clinical Presentation Patterns

ATN typically presents with:

• Acute kidney injury in the immediate post-insult period (hours to days)
• Most common in post-transplant period (<1 week) from cadaver grafts 6
• Associated with sepsis, volume depletion, nephrotoxic medications 7
• Generally reversible with supportive care once the insult is removed

GN presents with:

• Active urine sediment with dysmorphic RBCs, RBC casts
• Proteinuria (often nephrotic-range >3.5 g/day)
• Hematuria (microscopic or gross)
• Variable timing: acute rejection (1 week-1 month post-transplant), chronic forms (>3 months) 6
• May present as rapidly progressive GN with crescents (≥50% of glomeruli) 4

Critical Diagnostic Pitfalls

Gross hematuria from GN can cause secondary ATN, creating diagnostic confusion 8, 9. When patients with glomerular disease develop acute renal failure after gross hematuria, the tubular lesions from intraluminal erythrocytes and casts may be more severe than the glomerular pathology. This entity is reversible with supportive care alone and does not require immunosuppression 9. Review of urinary sediment showing intraluminal erythrocytes and tubular debris helps identify this scenario.

Histopathologic Differentiation

On kidney biopsy:

ATN shows 1:

• Tubular cell sloughing (39.4% of cases)
• Tubular epithelial flattening/simplification (37.7%)
• Tubular dilatation (37.3%)
• Tubular cell necrosis (31.8%)
• Minimal to absent glomerular pathology
• Negative or minimal immunofluorescence

GN shows 4, 5:

• Glomerular hypercellularity (mesangial, endocapillary, or extracapillary)
• Crescents (cellular, fibrocellular, or fibrous)
• Fibrinoid necrosis with GBM disruption
• Positive immunofluorescence: granular deposits (immune complex GN), linear deposits (anti-GBM), or dominant C3 (C3 glomerulopathy)
• ANCA positivity in serum (80-90% of pauci-immune GN) 4

Treatment Implications

ATN management 7, 2:

• Supportive care with fluid optimization
• Remove nephrotoxic agents
• Avoid NSAIDs and aminoglycosides during recovery phase
• No role for immunosuppression
• Monitor for progression to chronic kidney disease

GN management 10, 11:

• Crescentic/necrotizing GN: High-dose glucocorticoids plus cyclophosphamide or rituximab (similar to ANCA vasculitis protocol)
• Immune complex GN: Disease-specific immunosuppression (MMF, glucocorticoids, rituximab depending on etiology)
• C3 glomerulopathy: MMF plus glucocorticoids initially; consider eculizumab if refractory 10
• Supportive care alone if eGFR <30 mL/min/1.73 m² without active crescentic/necrotizing features 10

Coexistence Scenarios

Both conditions can coexist 12, 13, 4. Secondary diagnoses unrelated to primary GN—such as drug-induced ATN, acute tubular injury from sepsis, or ischemic ATN—should be listed separately in pathology reports 4. In COVID-19, both viral-mediated tubular injury and glomerulonephritis have been reported as distinct pathologies 12.

The key clinical decision point: Distinguishing these entities prevents unnecessary immunosuppression in ATN (which carries significant morbidity) while ensuring timely treatment of GN to prevent irreversible glomerulosclerosis and chronic kidney disease 14.